PMID- 37903568
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231114
IS  - 2056-5933 (Electronic)
IS  - 2056-5933 (Linking)
VI  - 9
IP  - 4
DP  - 2023 Oct
TI  - Serum calprotectin and renal function decline in ANCA-associated vasculitides: a 
      post hoc analysis of MAINRITSAN trial.
LID - 10.1136/rmdopen-2023-003477 [doi]
LID - e003477
AB  - OBJECTIVE: Serum calprotectin appears to be an interesting biomarker associated 
      with renal vascular disease activity in antineutrophil cytoplasm antibody 
      (ANCA)-associated vasculitis (AAV). The aim of this study was to assess whether 
      serum calprotectin levels can predict decline in renal function in AAV patients 
      receiving maintenance therapy. METHODS: Serum calprotectin levels were assessed 
      at inclusion and month 6 in AAV patients, in complete remission after induction 
      therapy, randomly assigned to rituximab or azathioprine. Renal function decline 
      was defined as a 25% decrease in estimated glomerular filtration rate (eGFR) and 
      a change in the eGFR category, or a decrease of 15 mL/min/1.73 m(2). Relapse was 
      defined as a Birmingham Vasculitis Activity Score >0 attributable to active 
      vasculitis. RESULTS: Seventy-six AAV were included. Serum calprotectin increased 
      from baseline to month 6 in patients with renal function decline (7940 (-226.0, 
      28 691) ng/ml vs -4800 (-18 777, 3708) ng/ml; p<0.001). An increase of 
      calprotectin level was associated with a higher risk of subsequent renal function 
      decline even after adjustment (OR 6.50 (95% CI 1.7 to 24.9) p=0.006). A 
      significantly higher risk of relapse was observed in proteinase 3- AAV patients 
      with an increase of serum calprotectin levels (OR 5.6 (95% CI 1.0 to 31.2), 
      p=0.03). CONCLUSION: An increase in serum calprotectin by month 6 compared with 
      inclusion during remission-maintenance therapy in AAV was associated with a 
      higher risk of renal function decline in the following 12 months. TRIAL 
      REGISTRATION NUMBER: NCT00748644.
CI  - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Romand, Xavier
AU  - Romand X
AUID- ORCID: 0000-0003-2222-1456
AD  - CNRS, UMR 5525, T-RAIG, TIMC, CHU Grenoble Alpes, Universite Grenoble Alpes, 
      Grenoble, France xromand@chu-grenoble.fr.
FAU - Paclet, Marie Helene
AU  - Paclet MH
AD  - CNRS, UMR 5525, T-RAIG, TIMC, CHU Grenoble Alpes, Universite Grenoble Alpes, 
      Grenoble, France.
FAU - Chuong, Minh Vu
AU  - Chuong MV
AD  - CNRS, UMR 5525, T-RAIG, TIMC, CHU Grenoble Alpes, Universite Grenoble Alpes, 
      Grenoble, France.
FAU - Gaudin, Philippe
AU  - Gaudin P
AD  - CNRS, UMR 5525, T-RAIG, TIMC, CHU Grenoble Alpes, Universite Grenoble Alpes, 
      Grenoble, France.
FAU - Pagnoux, Christian
AU  - Pagnoux C
AD  - Vasculitis clinic, Mount Sinai Hospital, Toronto, Ontario, Canada.
FAU - Guillevin, Loic
AU  - Guillevin L
AD  - Universite de Paris, Paris, France.
AD  - Department of Internal Medicine, National Referral Center for Rare Systemic 
      Autoimmune Diseases, Hopital Cochin APHP-Centre Universite Paris (CUP), Paris, 
      France.
FAU - Terrier, Benjamin
AU  - Terrier B
AUID- ORCID: 0000-0001-6612-7336
AD  - Universite de Paris, Paris, France.
AD  - Department of Internal Medicine, National Referral Center for Rare Systemic 
      Autoimmune Diseases, Hopital Cochin APHP-Centre Universite Paris (CUP), Paris, 
      France.
FAU - Baillet, Athan
AU  - Baillet A
AUID- ORCID: 0000-0001-6006-2519
AD  - CNRS, UMR 5525, T-RAIG, TIMC, CHU Grenoble Alpes, Universite Grenoble Alpes, 
      Grenoble, France.
LA  - eng
SI  - ClinicalTrials.gov/NCT00748644
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - RMD Open
JT  - RMD open
JID - 101662038
RN  - 0 (Leukocyte L1 Antigen Complex)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Humans
MH  - *Leukocyte L1 Antigen Complex
MH  - Rituximab
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/diagnosis/drug 
      therapy
MH  - Recurrence
MH  - Kidney/physiology
PMC - PMC10619089
OTO - NOTNLM
OT  - autoimmune diseases
OT  - granulomatosis with polyangiitis
OT  - systemic vasculitis
COIS- Competing interests: Roche has provided rituximab for the MAINRITSAN trial. 
      MAINRITSAN trial was supported by the French Ministry of Health. XR reported 
      personal fees from Abbvie, MSD, UCB, Novartis, Celltrion Healthcare, Galapagos 
      and CHUGAI pharma for presentations, speakers or educational events.MHP did not 
      report any other conflicts of interest. MVC did not report any other conflicts of 
      interest. PG did not report any other conflicts of interest. CP reported 
      receiving grant from Pfizer, TEVA, Roche and personal fees from GSK, Roche, 
      Amgen, Pfizer for lectures, presentations, speakers, manuscript writing or 
      educational events and from Sanofi, ChemoCentryx, AstraZeneca, InflaRx and Otsuka 
      for participation on a data safety monitoring board or advisory board. LG did not 
      report any other conflicts of interest. BT reported receiving consulting fees 
      from Roche, Chugai, GSK and AstraZeneca. AB did not report any other conflicts of 
      interest.
EDAT- 2023/10/31 00:42
MHDA- 2023/11/02 12:43
PMCR- 2023/10/30
CRDT- 2023/10/30 21:12
PHST- 2023/07/07 00:00 [received]
PHST- 2023/10/02 00:00 [accepted]
PHST- 2023/11/02 12:43 [medline]
PHST- 2023/10/31 00:42 [pubmed]
PHST- 2023/10/30 21:12 [entrez]
PHST- 2023/10/30 00:00 [pmc-release]
AID - rmdopen-2023-003477 [pii]
AID - 10.1136/rmdopen-2023-003477 [doi]
PST - ppublish
SO  - RMD Open. 2023 Oct;9(4):e003477. doi: 10.1136/rmdopen-2023-003477.